RxDoctor Payments Data

Christopher Mogren

Family · Springfield, ILNPI 1417147927

Payments from drug & device makers

$5,949in general payments, 2019–2025

Across 204 payments — averaging $29.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$816
  • Johnson & Johnson$731
  • Madrigal Pharmaceuticals$497
  • Aimmune Therapeutics, Inc.$337
  • Phathom Pharmaceuticals, Inc.$264
  • plus $1K from 8 others

What the payments were for

  • Food & beverage$5,74897%
  • Education$2003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,949 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$11,421
Medicare patients
95
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$372,946
IbsrelaTenapanor Hcl44$85,924
ZenpepLipase/Protease/Amylase12$59,485
LinzessLinaclotide48$35,546
Mesalamine22$23,500
TrulancePlecanatide20$20,541
Dicyclomine Hcl104$1,762
Omeprazole169$1,713
Famotidine138$1,661
CholestyramineCholestyramine (With Sugar)15$1,463
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates21$1,349
Pantoprazole Sodium56$1,005
Ondansetron Hcl25$721
Ondansetron OdtOndansetron32$710
Mesalamine ErMesalamine13$664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$731$372,94612 claims
Ardelyx, Inc.Ibsrela$187$85,92444 claims
Aimmune Therapeutics, Inc.Zenpep$337$59,48512 claims
AbbVieLinzess$2,144$35,54648 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$186$20,54120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →